Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
$11.23
+2.8%
$12.47
$10.47
$29.12
$156.61M0.6671,834 shs108,712 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.69
+4.7%
$3.62
$2.51
$9.37
$103.46M0.52306,320 shs309,661 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$3.00
-1.0%
$2.83
$2.36
$4.92
$226.64M0.43763,200 shs685,050 shs
WOK
WORK Medical Technology Group
$0.74
+4.1%
$0.62
$0.36
$8.45
$10.38MN/A1.10 million shs29,435 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
+3.12%-1.71%-2.85%-29.18%-58.00%
Pulmonx Corporation stock logo
LUNG
Pulmonx
-1.91%-13.76%-17.36%-62.65%-58.68%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
+1.00%+5.21%+20.24%-13.18%-31.14%
WOK
WORK Medical Technology Group
-1.30%-9.41%+1.59%+20.53%+71,109,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
3.7645 of 5 stars
3.82.00.03.60.71.70.6
Pulmonx Corporation stock logo
LUNG
Pulmonx
3.0497 of 5 stars
3.35.00.00.00.63.30.6
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
1.1447 of 5 stars
1.03.00.04.20.01.70.6
WOK
WORK Medical Technology Group
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
3.50
Strong Buy$20.0078.09% Upside
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.63
Moderate Buy$11.53328.44% Upside
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.00
Hold$3.00N/A
WOK
WORK Medical Technology Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest WOK, OSUR, LUNG, and ANIK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.15
5/19/2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingIn-Line ➝ In-Line$3.00 ➝ $3.00
5/12/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/17/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/16/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
$119.91M1.34$0.10 per share114.48$10.51 per share1.07
Pulmonx Corporation stock logo
LUNG
Pulmonx
$83.79M1.29N/AN/A$2.17 per share1.24
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$185.83M1.21$0.04 per share78.05$5.50 per share0.55
WOK
WORK Medical Technology Group
$11.51M0.94N/AN/A$1.10 per share0.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
-$56.38M-$3.88N/AN/AN/A-41.28%-7.22%-5.64%8/6/2025 (Estimated)
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$19.50M-$0.42N/AN/AN/A-19.77%-5.86%-5.20%8/5/2025 (Estimated)
WOK
WORK Medical Technology Group
-$3.49MN/A0.00N/AN/AN/AN/AN/A

Latest WOK, OSUR, LUNG, and ANIK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
WOK
WORK Medical Technology Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.73
4.53
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.38
4.97
4.29
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
12.34
10.94
WOK
WORK Medical Technology Group
N/A
1.03
0.87

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
91.53%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%
WOK
WORK Medical Technology Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
30014.34 million12.96 millionOptionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
25040.26 million37.52 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
84074.80 million71.88 millionOptionable
WOK
WORK Medical Technology Group
22614.59 millionN/AN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Anika Therapeutics stock logo

Anika Therapeutics NASDAQ:ANIK

$11.23 +0.31 (+2.84%)
Closing price 04:00 PM Eastern
Extended Trading
$11.24 +0.00 (+0.04%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$2.69 +0.12 (+4.67%)
Closing price 04:00 PM Eastern
Extended Trading
$2.76 +0.07 (+2.45%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

OraSure Technologies stock logo

OraSure Technologies NASDAQ:OSUR

$3.00 -0.03 (-0.99%)
Closing price 04:00 PM Eastern
Extended Trading
$3.00 +0.00 (+0.17%)
As of 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

WORK Medical Technology Group NASDAQ:WOK

$0.74 +0.03 (+4.06%)
Closing price 04:00 PM Eastern
Extended Trading
$0.74 0.00 (-0.14%)
As of 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

WORK Medical Technology Group Ltd. engages in developing health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.